Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kadmon’s cGVHD drug gets FDA orphan drug designation
The FDA’s orphan designation is granted to encourage the development of potential products for rare conditions that affect less than 200,000 patients annually in the US. cGVHD is
The FDA’s orphan designation is granted to encourage the development of potential products for rare conditions that affect less than 200,000 patients annually in the US. cGVHD is
The Zika vaccine showed both safety and the ability to induce high levels of antibodies in all the 40 participants of the trial against the mosquito-borne virus in
Iclaprim, which is a diaminopyrimidine antibiotic, met its primary endpoint and was found to be well tolerated during the phase 3 clinical trial dubbed REVIVE-2. Featuring 600 ABSSSI
Under the deal, the partnership will develop CytomX Probody T-cell engaging bispecific against the epidermal growth factor receptor (EGFR), a validated oncology target expressed on multiple human cancer
The company received series E financing, which was supported by existing investors such as dievini Hopp Biotech, Wellington Partners and AT Impf GmbH, as well as by new
Jenner Institute of Oxford University and Vaccitech, which was spun out of it, had developed the new flu vaccine. Over 10,000 people aged 65 and over will be
Adcetris is an antibody-drug conjugate (ADC) directed to CD30, a determining marker of Hodgkin lymphoma. The ADC includes an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to
An anti-von Willebrand factor (vWF) nanobody, Caplacizumab met both the primary endpoint and key secondary endpoints of the phase 3 trial, dubbed HERCULES. The late-stage trial evaluated it against
The Pennsylvania-based specialty pharmaceutical company said that the phase 2 study FAB-C had met its primary endpoint by recording an improvement by 46% at week twelve in the
Through the investment, Evotec which calls itself as a drug discovery alliance and development partnership company has become the first strategic shareholder in Exscientia. Evotec with over 1,800